Every day, hospital pharmacists and nurses manually prepare thousands of injectable medicines in sterile cleanrooms—a slow, error-prone process that is buckling under the weight of newer, more complex personalised drugs. This matters because the current system for aseptic compounding—mixing and sterilising injectable drugs before they reach a patient—cannot keep up. Demand is rising, staff are stretched, and many medicines have short shelf-lives that force last-minute preparation. The project treats formulation, manufacture, and distribution as a single system, aiming to redesign it from scratch. If successful, the research could shift much of this work out of hospitals and into automated, centralised facilities using robotics and AI. Medicines would be reformulated for longer stability and simpler administration, then distributed through a hub-and-spoke model. This would free up pharmacists and nurses for direct patient care, reduce waste, and make injectable treatments more accessible in community settings. The impact is largely invisible to patients—it changes the industrial backbone of how medicines are made and delivered, not the drugs themselves.
View original technical description
Aseptic compounding is an area where practice has been transformed by the emergence of more complex, personalised medicines. The demands on aseptic dispensing are continually increasing, with clinical teams relying on increasingly complex compounds for treatments given every single day. This Prosperity Partnership aims to create a platform that will transform the future use of injectable medicines in the UK and globally. We envisage, ultimately, a range of reformulated injectable medicines suited to the setting in which they are administered, whether in the community or a hospital, manufactured through an automated process dramatically reducing the demand placed on healthcare resource required to deliver them in whatever setting is appropriate. This potentially requires a wholesale reconfiguration of compounding service in England around a hub and spoke model with high degrees of standardisation and the adaption/adoption of new approaches to automation making more efficient use of resources both in pharmacy/compounding and in the nursing workforce transforming the use of injectable medicines. Underpinning the interlinked delivery of these medicines is a continual drive for extended shelf-lives (stability), simplicity in administration, volume of manufacture, supply chain and cost reduction. Our project focusses on the nexus of these points, considering medicine formulation, manufacture and distribution as a whole system, where elements of the compounding process can occur across different sites, with different scalability and optimisation depending on both use/requirement and shelf-life/complexity of formulation and aseptic manufacturing facility requirements. This incorporates implementing robotics manufacturing and AI into the heavily regulated area of high variation medicines production.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know